GT BIOPHARMA, INC. Warrants and Rights Outstanding
GT BIOPHARMA, INC. (GTBP) had Warrants and Rights Outstanding of $44.00 thousand as of 2025-05-31, per its 10-Q/A filed 2026-03-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:WarrantsAndRightsOutstanding · last filed 2026-03-06
- 2025-05-31: Warrants and Rights Outstanding $44.00K.
- 2021-09-30: Warrants and Rights Outstanding $340.00K.
- 2021-06-30: Warrants and Rights Outstanding $842.00K.
- 2021-03-31: Warrants and Rights Outstanding $362.00K.
| Period end | Warrants and Rights Outstanding |
|---|---|
| 2025-05-31 | $44.00K 10-Q/A · filed 2026-03-06 |
| 2021-09-30 | $340.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $842.00K 10-Q/A · filed 2021-12-29 |
| 2021-03-31 | $362.00K 10-Q · filed 2021-05-17 |
| 2020-12-31 | $383.00K 10-Q/A · filed 2021-12-29 |
| 2020-07-31 | $153.00K 10-K · filed 2021-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |